#ACR22 Abstr#0799 Is Evusheld effective in patients on B-cell depleting therapies? Early data (Jan-May 22) from @CCalabreseDO @LCalabreseDO are encouraging: 13/417 (3%) breakthrough infection in fully vac pts, 1 hospitalised. More data needed for Omicron subvariants @RheumNow https://t.co/g4Y1IMO67X

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty

#ACR22 Abstr#0783. Rituximab impacts on humoral immunity. Our study on 400 RMD pts showed: Breakthrough infection 30% mostly mild; Severe 4%; 1 death Poor outcomes predicted by comorbidities & low IgG Risk reduced by 50% with each vac dose OK for RTX if vaccinated @RheumNow https://t.co/xyJsukm1Rh

☝️Remember: Not all skin thickening is SSc! 🔸Lipodermatosclerosis is a differential. Has an inverted champagne bottle appearance - caused by venous stasis and venous HTN #ACR22 @RheumNow #Scleroderma #RheumTwitter https://t.co/joWWn6BnVC

Song et al. Korean study shows better persistence of tocilizumab than TNFi as first-line biologic in RA. No difference in incidence of TB. @RheumNow #ACR22 Abstr#0887 https://t.co/EuQkfDZd77 https://t.co/VxJmKEzAVY

• Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necr…

Lanz et al. Inverse relationship between number of ACPAs and subclinical ILD. Effect appears confined to African American and Hispanic participants. Not sure what to make of this at all. @RheumNow #ACR22 Abstr#1203 https://t.co/Ok3PCLFyxe https://t.co/UHlI6HOUmc

• The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical I…

Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bimekizumab works across spectrum of axSpA (not surprisingly). @RheumNow #ACR22 Abstr#0544 https://t.co/XVGBgBQpTH https://t.co/39zW5Ex9xh

• Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients wi…

Hanlon @MeganHanlon4 @dougveale et al. Loss of macrophage homeostasis occurs in pre-RA, and appears to be an early factor in RA development @RheumNow #ACR22 Abstr#0554 https://t.co/UL1jVGVlrA https://t.co/i1WWQlHs2m

• Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Cl…

Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4

• COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy ver…

Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk

• Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatm…

Day 2: Tips to avoid burnout. I know it’s Sunday morning but a dose of #physicalactivity will keep the mind and body sane. Dare to accept challenge? #ACRVirtual5K Run #ACR22 #rheumatologyrunners #wellbeing #foggy @RheumNow #RheumPix https://t.co/N9ulz8KPVw

Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539 https://t.co/mb3Eof2Uiv https://t.co/3i3ZTY25ru

• Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Pat…

Rech et al. 18 month results of ARIAA, 6 months abatacept in pre-RA, 1 year drug-free follow-up. 35% vs 65% developed RA. MRI response 57% vs 29%. @RheumNow #ACR22 Abstr#0530 https://t.co/35M2sPkIbW https://t.co/S8K39jkCh0

• You searched for 0530 - ACR Meeting Abstracts

Ab0675 #ACR22 DAH in APLS 61 pts w APS, incident DAH 85% h/o VTE, 51% thrombocyt 43% valvulopathy 74% were on a/c at time of DAH Relapse rate: 41% at 1 yr, 26% w/in 6 mos!!! Risks: triple pos, thrombocyt, IVIG, PLEX, ventilation Mortality 19% 1 yr, 38% 5 yrs @RheumNow #ACRBest https://t.co/g1uz2Giilc

Ab0676 #ACR22 Adrenal hemorrhage in APLS 59 pts from SLE cohort + 181 from lit review 65% prior VTE, 12% CVA, 24% OB morbidity 46% thrombocyt, 21% had SLE 58% on a/c 69% b/l hemorrhage 63% adrenal insuff Radiol remission: 6% at 1 yr, 41% at 5yr Death 2% 1 yr, 11% at 5 @RheumNow https://t.co/EacifcN7Sd